News Feed

MPN News

MPN rss feedThe MPN News feed provides frequent updates on the latest happenings in the MPN World. Fresh content, with brief summary is automatically updated frequently from reliable sources.  Just click on the red hyperlink to pull up the complete news item.

Make PV Reporter your “starting point” for all MPN related news.

 

UT (University of Texas) San Antonio makes Dr. Ruben Mesa head of their Cancer Center Dr Ruben Mesa, one of the leading MPN Specialist in the world is accepting the role of the head of UT at San Antonio Cancer Center, where he will remain focused on MPN's. “Dr. Mesa's [...]
Thu, Jun 15, 2017, Continue reading at the source
The Report, “Essential Thrombocythemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Essential Thrombocythemia Report is to understand the market and pipeline status of the drugs [...]
Thu, Jun 15, 2017, Continue reading at the source
The following article features coverage from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Click here to read more of Cancer Therapy Advisor‘s conference coverage. Momelotinib, an oral Janus kinase (JAK) inhibitor, is non-inferior to ruxolitinib in reducing spleen volume, though not for improving disease-related [...]
Thu, Jun 15, 2017, Continue reading at the source
Myelofibrosis A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination of INCB050465 and ruxolitinib in subjects with myelofibrosis Talk to your doctor if you are [...]
Wed, Jun 14, 2017, Continue reading at the source
Click here to view statement from MPN Advocacy & Education International Click here to read message to patients [...]
Wed, Jun 14, 2017, Continue reading at the source
Dear MPN Patient Community, The Mayo Clinic Cancer Center is a very special place where people come together joined by a mission to put patients first in alleviating the burden of Cancer. The Mayo Clinic has been my professional home for my entire career since 1991, with 18 years in training [...]
Wed, Jun 14, 2017, Continue reading at the source
Immunofluorescence of single human cell stained grown in tissue culture, stained with multiple antibodies and visualized via confocal microscopy
Abstract Myeloproliferative neoplasm cells recruit Gli1 positive mesenchymal stromal cells to transdifferentiate into fibrosis-causing myofibroblasts, a process that can be inhibited by a Gli inhibitor. Bone marrow fibrosis (BMF), characterized by deposition of reticulin and collagen fibers in the marrow, is a hallmark of primary myelofibrosis (PMF) and other myeloproliferative neoplasms (MPNs). [...]
Mon, Jun 05, 2017, Continue reading at the source
Understanding Polycythemia Vera (PV), A Rare Blood Cancer Behind the Mystery, Polycythemia Vera Every year, millions of patients, families and caregivers are impacted by cancer in the United States. Some cancers are well-known, but others are quite rare. Polycythemia Vera (PV) is part of a group of rare blood cancers called [...]
Fri, Apr 28, 2017, Continue reading at the source
Annual Hematology Meeting Updates: CML and MPN
A Solid Summary on the Latest MPN Research in 2017 Drs. Joseph R. Mikhael and Ruben A. Mesa analyze and discuss pertinent clinical studies and late breaking updates pertaining to the care of patients with chronic myelogenous leukemia (CML) and myeloproliferative neoplasms (MPN) in this Best of the Day discussion from [...]
Sun, Jan 29, 2017, Continue reading at the source
Long Term Exposure to Radiation puts you at higher risk for MPN A Savannah River Site Worker The Savannah River Site is on a list of qualified places for Special Exposure Cohort Employees (SEC) The SEC allows eligible claimants to be compensated without the completion of a NIOSH radiation dose reconstruction or determination [...]
Mon, Jan 02, 2017, Continue reading at the source
For anyone who lives a fast-paced life, it is easy to sometimes forget our need to take care of ourselves and to listen to our bodies. It is easy to get distracted from the importance of a healthy lifestyle when it seems there is so much to be done. But it [...]
Tue, Mar 15, 2016, Continue reading at the source
February 29th is Rare Disease Day: 4 Reasons You Should Care Even though MPN patients who have a rare disease many may have never heard of "Rare Disease Day" and know next to nothing about the impact rare disorders have on society. Rare diseases play a larger role in public [...]
Mon, Feb 29, 2016, Continue reading at the source
It's World Cancer Day There has been, from time to time, a question about whether myeloproliferative neoplasms are cancers. Let's be clear, they are. But don't take our word for it. Cancer Support Community defines Myeloproliferative Neoplasms (MPNs) as types of blood cancers that overproduce blood cells in the bone [...]
Mon, Feb 01, 2016, Continue reading at the source
For the past several months we've kept you informed and taking action on Medicare's pending decision of whether to provide coverage for people with myelofibrosis seeking a stem cell transplant. Currently there is no official ruling from Medicare on whether this treatment is covered, leaving many patients to risk paying [...]
Tue, Jan 12, 2016, Continue reading at the source
Each year for the past three years, Cure Magazine and Incyte Corporation have recognized efforts within the MPN community with their MPN Hero award. The two categories are commitment to the community or individual. Past winners have included Ruben Mesa, Zhenya Senyak, Joyce Niblack, Richard Silver, and many more. We [...]
Sun, Dec 27, 2015, Continue reading at the source
According to a paper published in Nature Medicine, the drug MLN8237 (or Alisertib) has reduced tumor cells, blood counts and fibrosis in mouse models of myelofibrosis. Reports John Crispino, PhD, "This new paper shows that Alisertib has an anti-tumor effect in samples of myelofibrosis, similar to what we saw in [...]
Tue, Dec 01, 2015, Continue reading at the source


Check out more resources at MPN Cancer Connection!Click here
error: Content is protected !!